SK16072000A3 - Deriváty 3-(amino- alebo aminoalkyl)pyridinónu a ich použitie - Google Patents

Deriváty 3-(amino- alebo aminoalkyl)pyridinónu a ich použitie Download PDF

Info

Publication number: SK16072000A3
Authority: SK; Slovakia
Prior art keywords: group; alkyl; pyridinone; amino; substituted
Prior art date: 1998-04-27

Application number

SK1607-2000A

Other languages

English (en)

Slovak (sk)

Inventor

�Mile Bisagni

Val�Rie Dolle

Chi Hung Nguyen

Claude Monneret

David Grierson

Anne-Marie Aubertin

Original Assignee

Centre National De La Recherche Scientifique

Institut Curie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-27

Filing date

1999-04-27

Publication date

2002-04-04

1999-04-27 Application filed by Centre National De La Recherche Scientifique, Institut Curie filed Critical Centre National De La Recherche Scientifique

2002-04-04 Publication of SK16072000A3 publication Critical patent/SK16072000A3/sk

Links

201000010099 disease Diseases 0.000 title claims abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 9
125000004103 aminoalkyl group Chemical group 0.000 title abstract description 8
150000001875 compounds Chemical class 0.000 claims abstract description 50
238000000034 method Methods 0.000 claims abstract description 19
238000002360 preparation method Methods 0.000 claims abstract description 5
-1 dimethylethoxy Chemical group 0.000 claims description 40
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 21
125000004432 carbon atom Chemical group C* 0.000 claims description 18
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
150000005299 pyridinones Chemical class 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 12
125000003118 aryl group Chemical group 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
150000002641 lithium Chemical class 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
125000001424 substituent group Chemical group 0.000 claims description 8
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
230000007062 hydrolysis Effects 0.000 claims description 6
238000006460 hydrolysis reaction Methods 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
229910052744 lithium Inorganic materials 0.000 claims description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
125000003342 alkenyl group Chemical group 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
125000005110 aryl thio group Chemical group 0.000 claims description 4
125000004104 aryloxy group Chemical group 0.000 claims description 4
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000002950 monocyclic group Chemical group 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
208000031886 HIV Infections Diseases 0.000 claims description 3
208000037357 HIV infectious disease Diseases 0.000 claims description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 claims description 2
150000001204 N-oxides Chemical class 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000002877 alkyl aryl group Chemical group 0.000 claims description 2
125000004414 alkyl thio group Chemical group 0.000 claims description 2
150000003935 benzaldehydes Chemical class 0.000 claims description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
239000010949 copper Substances 0.000 claims description 2
VPIJTROCWADCRU-UHFFFAOYSA-N copper;methylsulfanylmethane Chemical compound [Cu].CSC VPIJTROCWADCRU-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000002541 furyl group Chemical group 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000002524 organometallic group Chemical group 0.000 claims description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000002769 thiazolinyl group Chemical group 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
230000001131 transforming effect Effects 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 3
101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
230000001590 oxidative effect Effects 0.000 claims 1
150000003222 pyridines Chemical class 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 12
102100034343 Integrase Human genes 0.000 abstract description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract description 3
125000006186 3,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C([H])=C1C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 39
241000713772 Human immunodeficiency virus 1 Species 0.000 description 20
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 12
125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
239000000543 intermediate Substances 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
230000001177 retroviral effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
YNOHDVUYAXBTFK-UHFFFAOYSA-N n-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-2,2-dimethylpropanamide Chemical compound CCC1=CC(NC(=O)C(C)(C)C)=C(OC)N=C1C YNOHDVUYAXBTFK-UHFFFAOYSA-N 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
FHQCHOTUQBIXHY-UHFFFAOYSA-N 3-(dimethylamino)-4-[(3,5-dimethylphenyl)methyl]-5-ethyl-6-methyl-1h-pyridin-2-one Chemical compound CCC1=C(C)NC(=O)C(N(C)C)=C1CC1=CC(C)=CC(C)=C1 FHQCHOTUQBIXHY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000012267 brine Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
PVZMRETVOJGNDW-UHFFFAOYSA-N 3-amino-4-[(3,5-dimethylphenyl)methyl]-5-ethyl-6-methyl-1h-pyridin-2-one Chemical compound CCC1=C(C)NC(=O)C(N)=C1CC1=CC(C)=CC(C)=C1 PVZMRETVOJGNDW-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
101710137500 T7 RNA polymerase Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
SPXOYLTWMNEOCK-UHFFFAOYSA-N n-[4-[(3,5-dimethylphenyl)methyl]-5-ethyl-2-methoxy-6-methylpyridin-3-yl]-2,2-dimethylpropanamide Chemical compound CCC1=C(C)N=C(OC)C(NC(=O)C(C)(C)C)=C1CC1=CC(C)=CC(C)=C1 SPXOYLTWMNEOCK-UHFFFAOYSA-N 0.000 description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229940046166 oligodeoxynucleotide Drugs 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
QXDHXCVJGBTQMK-UHFFFAOYSA-N 1-(bromomethyl)-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(CBr)=C1 QXDHXCVJGBTQMK-UHFFFAOYSA-N 0.000 description 2
HDMHBHNRWDNNCD-UHFFFAOYSA-N 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine Chemical compound OCCOCN1C(=O)NC(=O)C(C)=C1SC1=CC=CC=C1 HDMHBHNRWDNNCD-UHFFFAOYSA-N 0.000 description 2
YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
239000003480 eluent Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
125000006184 2,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000006185 3,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
GCXPYFSPWQHIFU-UHFFFAOYSA-N 5-ethyl-2-methoxy-6-methylpyridin-3-amine Chemical compound CCC1=CC(N)=C(OC)N=C1C GCXPYFSPWQHIFU-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
101150079601 recA gene Proteins 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK1607-2000A 1998-04-27 1999-04-27 Deriváty 3-(amino- alebo aminoalkyl)pyridinónu a ich použitie SK16072000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8308298P	1998-04-27	1998-04-27
PCT/EP1999/003023 WO1999055676A1 (en)	1998-04-27	1999-04-27	3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases

Publications (1)

Publication Number	Publication Date
SK16072000A3 true SK16072000A3 (sk)	2002-04-04

Family

ID=22176061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1607-2000A SK16072000A3 (sk)	1998-04-27	1999-04-27	Deriváty 3-(amino- alebo aminoalkyl)pyridinónu a ich použitie

Country Status (27)

Country	Link
US (2)	US6451822B1 (cs)
EP (1)	EP1073637B1 (cs)
JP (1)	JP2002513004A (cs)
KR (1)	KR20010087128A (cs)
CN (1)	CN1303378A (cs)
AP (1)	AP2000001991A0 (cs)
AT (1)	ATE334966T1 (cs)
AU (1)	AU4137899A (cs)
BG (1)	BG104984A (cs)
BR (1)	BR9909976A (cs)
CA (1)	CA2330304A1 (cs)
CZ (1)	CZ20003978A3 (cs)
DE (1)	DE69932611T2 (cs)
EE (1)	EE200000620A (cs)
HR (1)	HRP20000716A2 (cs)
HU (1)	HUP0101595A3 (cs)
ID (1)	ID27502A (cs)
IL (1)	IL139239A0 (cs)
MX (1)	MXPA00010490A (cs)
NO (1)	NO20005387L (cs)
NZ (1)	NZ508297A (cs)
PL (1)	PL343685A1 (cs)
RU (1)	RU2000129671A (cs)
SK (1)	SK16072000A3 (cs)
TR (1)	TR200003113T2 (cs)
WO (1)	WO1999055676A1 (cs)
ZA (1)	ZA200006037B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6436972B1 (en) *	2000-04-10	2002-08-20	Dalhousie University	Pyridones and their use as modulators of serine hydrolase enzymes
US6803370B2 (en) *	2000-07-21	2004-10-12	Elan Pharmaceuticals, Inc.	Alpha amino acid derivatives—inhibitors of leukocyte adhesion mediated by VLA-4
WO2002024650A2 (en) *	2000-09-19	2002-03-28	Centre National De La Recherche Scientifique (Cnrs)	Pyridinone and pyridinethione derivatives having hiv inhibiting properties
US7998986B2 (en)	2001-12-21	2011-08-16	Exelixis Patent Company Llc	Modulators of LXR
US7482366B2 (en)	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
US7642277B2 (en) *	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
EP1608629A1 (en) *	2003-03-24	2005-12-28	F. Hoffmann-La Roche Ag	Benzyl-pyridazinons as reverse transcriptase inhibitors
EP1516873A1 (en) *	2003-09-22	2005-03-23	Facultés Universitaires Notre-Dame de la Paix	2-pyridinone derivatives, having HIV inhibiting properties
TW200613307A (en) *	2004-05-17	2006-05-01	Tibotec Pharm Ltd	4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones
MY148809A (en) *	2004-07-06	2013-05-31	Eisai R&D Man Co Ltd	Crystals of 1,2-dihydropyridine compound and their production process
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
US9040558B2 (en) *	2004-12-31	2015-05-26	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
RS53599B1 (sr)	2005-05-10	2015-02-27	Intermune, Inc.	Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
JP2009506123A (ja)	2005-08-29	2009-02-12	バーテックスファーマシューティカルズインコーポレイテッド	非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
DE602006020293D1 (de)	2005-08-29	2011-04-07	Vertex Pharma	3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin-kinasen nützlich sind
ATE548363T1 (de)	2005-08-29	2012-03-15	Vertex Pharma	3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
KR20080080373A (ko) *	2005-12-19	2008-09-03	신젠타 리미티드	살진균제로서 치환된 방향족 헤테로사이클 화합물
AU2008326784B2 (en) *	2007-11-20	2014-04-24	Merck Sharp & Dohme Corp.	Non-nucleoside reverse transcriptase inhibitors
JP5627574B2 (ja)	2008-06-03	2014-11-19	インターミューン，インコーポレイテッド	炎症性および線維性疾患を治療するための化合物および方法
WO2010009047A1 (en) *	2008-07-14	2010-01-21	Korea Research Institute Of Chemical Technology	Pyridone derivatives as non-nucleoside reverse transcriptase inhibitors
US8318737B2 (en)	2009-09-02	2012-11-27	Canthera Therapeutics Inc.	Compounds and compositions for treating cancer
US8349832B2 (en) *	2009-09-02	2013-01-08	Canthera Therapeutics	Compounds and compositions for treating cancer
CN102001994B (zh) *	2010-10-22	2014-07-09	北京大学	吡啶酮类hiv-1逆转录酶抑制剂的制备及其应用
CN103288719A (zh) *	2012-03-05	2013-09-11	苏州欧凯医药技术有限公司	非核甘艾滋病毒抑制物-吡啶酮类先导体的合成
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN106459042B (zh)	2014-04-02	2019-06-28	英特穆恩公司	抗纤维化吡啶酮类
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MA54549A (fr) *	2018-12-18	2022-03-30	Merck Sharp & Dohme	Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih
CN114026081B (zh) *	2019-05-22	2025-02-11	默沙东有限责任公司	作为针对hiv感染的细胞的选择性细胞毒性剂的吡啶酮衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5308854A (en) *	1990-06-18	1994-05-03	Merck & Co., Inc.	Inhibitors of HIV reverse transcriptase
AU641769B2 (en) *	1990-06-18	1993-09-30	Merck & Co., Inc.	Inhibitors of HIV reverse transcriptase
FR2737496B1 (fr) *	1995-07-31	1997-12-19	Centre Nat Rech Scient	4-aryl-thio-pyridin-2(1h)-ones, medicaments les contenant et leurs utilisations dans le traitement de maladies liees aux vih 1 et 2

1999
- 1999-04-27 EP EP99924870A patent/EP1073637B1/en not_active Expired - Lifetime
- 1999-04-27 NZ NZ508297A patent/NZ508297A/xx unknown
- 1999-04-27 EE EEP200000620A patent/EE200000620A/xx unknown
- 1999-04-27 AP APAP/P/2000/001991A patent/AP2000001991A0/en unknown
- 1999-04-27 RU RU2000129671/04A patent/RU2000129671A/ru unknown
- 1999-04-27 TR TR2000/03113T patent/TR200003113T2/xx unknown
- 1999-04-27 AU AU41378/99A patent/AU4137899A/en not_active Abandoned
- 1999-04-27 BR BR9909976-4A patent/BR9909976A/pt not_active IP Right Cessation
- 1999-04-27 WO PCT/EP1999/003023 patent/WO1999055676A1/en not_active Ceased
- 1999-04-27 CA CA002330304A patent/CA2330304A1/en not_active Abandoned
- 1999-04-27 IL IL13923999A patent/IL139239A0/xx unknown
- 1999-04-27 DE DE69932611T patent/DE69932611T2/de not_active Expired - Lifetime
- 1999-04-27 US US09/673,635 patent/US6451822B1/en not_active Expired - Fee Related
- 1999-04-27 AT AT99924870T patent/ATE334966T1/de not_active IP Right Cessation
- 1999-04-27 KR KR1020007011918A patent/KR20010087128A/ko not_active Withdrawn
- 1999-04-27 JP JP2000545836A patent/JP2002513004A/ja not_active Withdrawn
- 1999-04-27 SK SK1607-2000A patent/SK16072000A3/sk unknown
- 1999-04-27 ID IDW20002191A patent/ID27502A/id unknown
- 1999-04-27 CN CN99806829A patent/CN1303378A/zh active Pending
- 1999-04-27 HR HR20000716A patent/HRP20000716A2/hr not_active Application Discontinuation
- 1999-04-27 CZ CZ20003978A patent/CZ20003978A3/cs unknown
- 1999-04-27 PL PL99343685A patent/PL343685A1/xx unknown
- 1999-04-27 HU HU0101595A patent/HUP0101595A3/hu unknown
- 1999-04-27 MX MXPA00010490A patent/MXPA00010490A/es unknown
2000
- 2000-10-25 ZA ZA200006037A patent/ZA200006037B/en unknown
- 2000-10-26 NO NO20005387A patent/NO20005387L/no not_active Application Discontinuation
- 2000-11-24 BG BG104984A patent/BG104984A/xx unknown
2002
- 2002-07-15 US US10/194,240 patent/US6683079B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO20005387L (no)	2000-12-04
US6683079B2 (en)	2004-01-27
TR200003113T2 (tr)	2001-05-21
CZ20003978A3 (cs)	2001-09-12
DE69932611D1 (de)	2006-09-14
HUP0101595A3 (en)	2002-12-28
US6451822B1 (en)	2002-09-17
BG104984A (en)	2001-07-31
ID27502A (id)	2001-04-12
MXPA00010490A (es)	2002-10-17
PL343685A1 (en)	2001-08-27
RU2000129671A (ru)	2004-02-20
KR20010087128A (ko)	2001-09-15
AP2000001991A0 (en)	2000-12-31
ATE334966T1 (de)	2006-08-15
ZA200006037B (en)	2002-01-25
EE200000620A (et)	2002-04-15
JP2002513004A (ja)	2002-05-08
EP1073637B1 (en)	2006-08-02
NZ508297A (en)	2002-12-20
IL139239A0 (en)	2001-11-25
BR9909976A (pt)	2000-12-26
HRP20000716A2 (en)	2001-06-30
HUP0101595A2 (hu)	2001-11-28
DE69932611T2 (de)	2007-10-11
AU4137899A (en)	1999-11-16
CA2330304A1 (en)	1999-11-04
CN1303378A (zh)	2001-07-11
US20030125340A1 (en)	2003-07-03
WO1999055676A1 (en)	1999-11-04
NO20005387D0 (no)	2000-10-26
EP1073637A1 (en)	2001-02-07

Publication	Publication Date	Title
SK16072000A3 (sk)	2002-04-04	Deriváty 3-(amino- alebo aminoalkyl)pyridinónu a ich použitie
JP3447292B2 (ja)	2003-09-16	イミダゾピリジン及び胃腸の疾病の治療のためのその使用
CN107849037A (zh)	2018-03-27	用于治疗和预防乙型肝炎病毒感染的新的三环4‑吡啶酮‑3‑甲酸衍生物
JP2016169161A (ja)	2016-09-23	新規イミダゾピリジン化合物
CZ293725B6 (cs)	2004-07-14	Tetrazolové deriváty
CN107074880A (zh)	2017-08-18	二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
US6608058B2 (en)	2003-08-19	6-methylnicotinamide derivatives as antiviral agents
CN119173505A (zh)	2024-12-20	抗病毒杂环化合物
US6369057B1 (en)	2002-04-09	Quinoxalines, processes for their preparation and their use
CN106279150B (zh)	2018-02-09	吡啶稠环类化合物及其制备方法和用途
CN115160301B (zh)	2024-09-10	一种山荷叶素衍生物、其制备方法及用途
CN104804042A (zh)	2015-07-29	核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
JPH0649074A (ja)	1994-02-22	新規な９−フルオロ−７−オキソ−７Ｈ−ピリド［１，２，３−ｄｅ］［１，４］ベンズオキサジン−６−カルボン酸およびエステル
JP7603320B2 (ja)	2024-12-20	環内チアミジノアミド－アリールアミド系化合物及びｂ型肝炎を治療するためのその使用
WO1994017075A1 (en)	1994-08-04	Diazepin derivatives and antiviral compositions
EP0843663B9 (fr)	2003-10-29	4-aryl-thio-pyridin-2(1h)-ones, medicaments les contenant et leurs utilisations dans le traitement de maladies liees aux vih
JP2001506282A (ja)	2001-05-15	２０（ｓ）―７―エチル―９―（ｎ―メチル―ｎ―フェニル）アミジノ―カンプトテシン、その誘導体、その製造及びその抗腫瘍剤としての使用
WO2001038306A9 (en)	2003-06-19	Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives
CN113527296A (zh)	2021-10-22	一种流感病毒抑制剂
CN120424092B (zh)	2025-09-12	布尼亚病毒抑制剂及其制备方法和用途
JPH10505330A (ja)	1998-05-26	ハロゲンイミダゾピリジン
EP2420495A1 (en)	2012-02-22	Novel derivatives useful as antiviral agents
EP1191027A1 (en)	2002-03-27	Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists
EP1235806A1 (en)	2002-09-04	Novel 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives